Desmopressin Has No Beneficial Effect on Excessive Postoperative Bleeding or Blood Product Requirements Associated with Cardiopulmonary Bypass

Summary

Cardiopulmonary bypass during open-heart surgery is sometimes associated with excessive perioperative bleeding. Following a non-randomized study suggesting that desmopressin acetate (desmopressin) reduced blood product requirements in these patients, we conducted a double-blind, placebo-controlled randomized trial of desmopressin (0.3 µg/kg, i. v.) in 92 patients with overt bleeding and a prolonged bleeding time.

Mean blood loss during the first 24 h post-treatment was similar in the desmopressin and placebo groups (582 vs 465 ml, respectively; p = 0.15). Red-cell (p = 0.76), fresh frozen plasma (r = 0.66) and platelet unit (p = 0.74) requirements were also similar.

The haemostatic effect of desmopressin has been attributed to the release of von Willebrand factor (vWF) and a reduced bleeding time. In our study, vWF and factor VIII :C levels increased while the bleeding time decreased significantly at 90 min and 24 h in both groups and, although vWF and factor VIII: C levels were slightly higher in desmopressin-treated patients at 90 min, the difference was not significant. Thrombin-antithrombin III complex, fibrinogen degradation product and tissue plasminogen activator levels, reflecting activation of the coagulation and fibrinolytic systems, respectively, decreased uniformely in both groups.

We conclude that desmopressin is not useful in reducing blood loss or blood product requirements in patients with excessive immediate postoperative bleeding.

• References

• 1 Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-1697
• 2 Kohler M, Harris A. Pharmacokinetics and haematological effects of desmopressin. Eur J Clin Pharmacol 1988; 35: 281-285
• 3 Mannucci PM. Desmopressin, a non transfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-1455
• 4 Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemostas 1985; 11: 291-292
• 5 Hackmann T, Gascoyne RD, Naiman SC, Growe GH, Burchill LD, Jamieson WRE, Sheps SB, Schechter MT, Townsend GE. A trial of desmopressin (l-desamino-8-d-arginin vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 1989; 321: 1437-1443
• 6 Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L, Donovan A, Gaffney T, Bertele V, Troll J, Smith M, Chute LE. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. N Engl J Med 1986; 314: 1402-1406
• 7 Rocha E, Llorens R, Paramo JA, Arcas R, Cuesta B, Martin TrenorA. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?. Circulation 1988; 77: 1319-1323
• 8 Czer LSC, Bateman TM, Gray RJ, Raymond M, Stewart ME, Lee S, Goldfinger D, Chaux A, Matloff JM. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987; 9: 1139-1147
• 9 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
• 10 Caen J, Larrieu MJ, Samama M. L'hemostase – Méthodes d'exploration et diagnostic pratique. Expansion Scientifique Paris 197 180
• 11 Brown MC, Swygert TH, Whitten CW, Hebeler R. Desmopressin acetate following cardiopulmonary bypass surgery: evaluation of coagulation parameters. J Cardiothorac Vasc Anesth 1989; 3: 726-729
• 12 Hedderich GS, Petsikas DJ, Cooper BA, Leznoff M, Guerraty AJ, Poirier NL, Symes JF, Morin JE. Desmopressin acetate in uncomplicated coronary artery bypass surgery. A prospective randomized clinical trial. Can J Surg 1990; 33: 33-36
• 13 Anderson TLG, Solem JO, Tengborn L, Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990; 91: 872-878
• 14 Shiffrin SJ, Glass DD. DDAVP administration for postbypass bleeding. Pro: Desmopressin is of value in the treatment of post-cardiopulmonary bypass bleeding. J Cardiothorac Vasc Anesth 1991; 5: 285-289
• 15 Hackmann T, Naiman SC. DDAVP administration for postbypass bleeding. Con: Desmopressin is not of value in the treatment of post-cardiopulmonary bypass bleeding. J Cardiothorac Vasc Anesth 1991; 5: 290-293
• 16 Editorial: Desmopressin and arterial thrombosis. Lancet 1989 i. 938-940
• 17 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunoabsorbent assay. Thromb Haemostas 1988; 59: 101-106
• 18 Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; ii: 675-676
• 19 Stibbe J, Kluft C, Brommer EJ, Gomes M, Jong de DS, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 375-382
• 20 MacGregor IR, Roberts EM, Prowse CV, Broomhead AF, Ozolins M, Litka P. Fibrinolytic and haemostatic responses to desamino-D-Arginine vasopressine (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. Thromb Haemostas 1988; 59: 34-39